- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00565968
Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg
A Phase I Dose Escalation Trial to Evaluate Safety and Efficacy of Oral Sorafenib (Nexavar) With Regional Melphalan Via Normothermic Isolated Limb Infusion (ILI) in Patients With Intransit Extremity Melanoma
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib may also make tumor cells more sensitive to melphalan. Giving sorafenib together with an isolated limb infusion of melphalan may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib when given together with an isolated limb infusion of melphalan in treating patients with stage III melanoma of the arm or leg.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
OBJECTIVES:
Primary
- To determine the dose-limiting toxicities and maximum tolerate dose of systemic sorafenib tosylate in combination with regionally administered melphalan by isolated limb infusion in patients with stage IIIB or IIIC intransit extremity melanoma.
Secondary
- To characterize the safety and tolerability of this regimen in these patients.
- To assess the antitumor activity of this regimen, as evidenced by best overall response and duration of response, in these patients.
- To characterize the duration of progression-free survival of these patients.
- To characterize the pharmacokinetics of melphalan.
- To assess alterations in selected gene and protein expression profiles following treatment.
OUTLINE: This is a multicenter, dose-escalation study of sorafenib tosylate.
Patients receive oral sorafenib tosylate twice daily on days 1-14 and melphalan via isolated limb infusion into the upper or lower extremities on day 8.
Patients undergo tumor biopsies at baseline and in weeks 2 and 12 for gene expression analysis and western blot analysis. Patients also undergo blood sample collection periodically for pharmacokinetic analysis of melphalan.
After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 2 years.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
New York
-
New York, New York, Förenta staterna, 10065
- Memorial Sloan-Kettering Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
Histologically confirmed primary or recurrent extremity melanoma
Stage IIIB or IIIC disease
- Patients with stage IIIC disease must have had regional lymph nodes previously removed
- Disease to be treated by regional therapy must be distal to the planned site of tourniquet placement
Bidimensionally measurable disease by caliper or radiological method
Must have identifiable target lesions for disease assessment
- Patients with a single lesion must have archived tumor tissue available for research analysis
- No stage IV disease
No known brain metastasis
- Patients with neurological symptoms must have undergone a CT scan or MRI of the brain within the past 4 weeks to exclude brain metastasis
PATIENT CHARACTERISTICS:
- ECOG or Zubrod performance status 0-1
- Life expectancy > 6 months
- Hemoglobin ≥ 9.0 g/dL
- WBC ≥ 3,000/mm^3
- ANC ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
- ALT and AST ≤ 2.5 x ULN
- INR < 1.5 or PT/PTT normal
- Creatinine ≤ 1.5 x ULN
- Not pregnant or nursing
- Negative serum pregnancy test
- Fertile patients must use effective contraception
- Must have a palpable femoral or axillary pulse in the extremity to be treated
No cardiac disease, including any of the following:
- NYHA class III or IV congestive heart failure
- Unstable angina (i.e., angina symptoms at rest) or new onset angina within the past 3 months
- Myocardial infarction within the past 6 months
- No cardiac ventricular arrhythmias requiring antiarrhythmic therapy
- No uncontrolled hypertension, defined as systolic blood pressure (BP) > 150 mm Hg or diastolic BP > 90 mm Hg, despite optimal medical management
- No known HIV infection
- No chronic hepatitis B or C
- No active clinically serious infection > CTCAE grade 2
- No thrombotic or embolic events (e.g., cerebrovascular accident or transient ischemic attacks) within the past 6 months
- No signs or symptoms of vascular insufficiency (i.e., any history of blood clots or other ischemic peripheral vascular disease)
- No evidence or history of bleeding diathesis or coagulopathy
- No pulmonary hemorrhage or bleeding event ≥ CTCAE grade 2 within the past 4 weeks
- No other hemorrhage or bleeding event ≥ CTCAE grade 3 within the past 4 weeks
- No serious nonhealing wound, ulcer, or bone fracture
- No significant traumatic injury within the past 4 weeks
- No condition that impairs the patient's ability to swallow whole pills
- No malabsorption problem
- No known history of allergic reactions and/or hypersensitivity to melphalan, sorafenib tosylate, or any other agent used in the study
- No psychiatric condition or diminished capacity that would compromise giving informed consent, or interfere with study compliance
No history of other malignancies, except for any of the following:
- Adequately treated basal cell or squamous cell carcinoma of the skin
- Curatively treated in situ carcinoma of the uterine cervix, prostate cancer, or superficial bladder cancer
- Other curatively treated solid tumor with no evidence of disease for ≥ 5 years
PRIOR CONCURRENT THERAPY:
- Recovered from prior therapy
- No prior sorafenib tosylate
- Prior melphalan via isolated limb infusion allowed
- No antineoplastic therapy, radiotherapy, or any other investigational drug within the past 4 weeks
- No major surgery or open biopsy within the past 4 weeks
- No concurrent Hypericum perforatum (St. John wort) or rifampin
- Concurrent anti-coagulation treatment with warfarin or heparin allowed
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Sorafenib dose escalation
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Maximal tolererad dos
Tidsram: 1 år
|
1 år
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Säkerhet och tolerabilitet
Tidsram: 2 år
|
2 år
|
Antitumor activity, as evidenced by best overall response and duration of response
Tidsram: 3 years
|
3 years
|
Duration of progression-free survival
Tidsram: 3 years
|
3 years
|
Pharmacokinetics of melphalan
Tidsram: 3 years
|
3 years
|
Tumor gene and protein expression profiles following treatment
Tidsram: 3 years
|
3 years
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Douglas S. Tyler, MD, Duke Cancer Institute
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter histologisk typ
- Neoplasmer
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Neuroendokrina tumörer
- Nevi och melanom
- Melanom
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Antineoplastiska medel, Alkylering
- Alkyleringsmedel
- Myeloablativa agonister
- Proteinkinashämmare
- Sorafenib
- Melphalan
Andra studie-ID-nummer
- Pro00001344
- CDR0000575427
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Melanom (hud)
-
Alma LasersIndragenSkin ResurfacingFörenta staterna
-
Utah State UniversityAktiv, inte rekryterandeExcoriation (Skin-Picking) DisorderFörenta staterna
-
Syneron MedicalAvslutadSkin Resurfacing | RynkminskningFörenta staterna, Kanada
-
University of Split, School of MedicineAvslutadSkin Recovery i olika mänskliga hudskadamodellerKroatien
-
University of California, DavisAvslutadTarmmikrobiom | Hudmikrobiom | Gut Lipidom | Skin Lipidom | BlodlipidomFörenta staterna
-
Northwestern UniversityUniversity of Wisconsin, StoutAvslutadPerception of Skin of Color Clinics in African AmericansFörenta staterna
-
Centre Hospitalier le MansRekrytering
-
University of CatanzaroUniversity of Roma La SapienzaOkänd
-
The First Affiliated Hospital of Dalian Medical...OkändSår och skador | Trauma | Frakturer, Öppen | Skin ExpanderKina
-
NYU Langone HealthAvslutadDonator Site Complication | Skin Graft DisorderFörenta staterna
Kliniska prövningar på analys av genuttryck
-
Pusan National University HospitalAvslutad
-
Recep Tayyip Erdogan University Training and Research...Hacettepe UniversityAvslutadAmputation | Diabetisk polyneuropatiKalkon
-
Philips Consumer LifestyleAvslutad
-
Liao Jian AnRekryteringHuvud- och halscancerTaiwan
-
Kessler FoundationHar inte rekryterat ännu
-
Oregon Health and Science University4DMedicalAnmälan via inbjudanLungsjukdomar | KOL | Luftvägssjukdom | DyspnéFörenta staterna
-
University of California, San FranciscoRekryteringFriska | Fertilitetsstörningar | Manlig infertilitet | Infertilitet, manligFörenta staterna
-
Candela CorporationRekryteringMeibomisk körteldysfunktion | Torra ögonsjukdomFörenta staterna, Argentina
-
Claret MedicalMeditrial Europe Ltd.Avslutad
-
Kessler FoundationRekryteringAutismFörenta staterna